From myocardial hypertrophy to left ventricular failure: Role of neurohumoral systems;De l'hypertrophie à l'insuffisance cardiaque gauche: Rôle du système neuro-humoral

Praxis

Volumn 86, Issue 7, 1997, Pages 238-241

  Lerch, R ^a   Montessuit, Ch ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Aldissteson; Angiotensin II; Cardiac failure; Diasole dysfunction; Hypertrophy

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ALDOSTERONE; ANGIOTENSIN II; ARGIPRESSIN; ATRIAL NATRIURETIC FACTOR; NORADRENALIN; RENIN;

CONGESTIVE HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART STROKE VOLUME; HUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SYSTOLE;

ALDOSTERONE; ANGIOTENSIN II; ARGININE VASOPRESSIN; ATRIAL NATRIURETIC FACTOR; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; NEUROTRANSMITTER AGENTS; NOREPINEPHRINE; RENIN; STROKE VOLUME; SYSTOLE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 5844311097     PISSN: 16618157     EISSN: 16618165     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Kannel W. B., Dannenberg A. L., Levy D.: Population implications of electrocardiographic left ventricular hypertrophy. Am J Cardiol 1987;60: 851-931.
2. Kannel W. B., Belanger A. J.: Epidemiology of heart failure. Am Heart J 1991; 121: 951-957.
3. Navarro-Lopez F., Coca A., Pare J. C., De La Sierra A., Bosch X., Urbano Marquez A.: Left ventricular hypertrophy in asymptomatic essential hypertension: its relationship with aldosterone and the increase in sodium-proton exchanger activity.
4. Maron B. J., Pelliccia A., Spataro A., Granuta M.: Reduction in left ventricular wall thickness after deconditioning in highly trained Olympic athletes. Br Heart J 1993; 69: 125-128.
5. Swynghedauw B.: Physiopathologie de l'insuffisance cardiaque. Facteurs biologiques d'adaptation et de desadaptation du cœur a une surcharge mecanique chronique. Schweiz Med Wochenschr 1995; 125: 288-293.
6. Brilla C. G., Pick R., Tan L. B., Janicki J. S., Weber K. T.: Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 1990; 67: 1355-1364.
7. Francis G. S.: Neurohumoral mechanisms involved in congestive heart failure. Am J Cardiol 1985; 55: 15A-21A.
8. Remme W. J.: Therapeutic strategies and neurohormonal control in heart failure. Eur Heart J 1994; 15 (Suppl D): 129-138.
9. Weber K. T., Sun Y., Katwa L. C., Cleutjens J. P.: Connective tissue: a metabolic entity? J Mol Cell Cardiol 1995; 27: 107-120.
10. The Task Force on Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis of heart failure. Eur Heart J 1995; 16: 741-751.
11. Federmann M., Risti B., Hess O. M.: Linksventrikulare Insuffizienz: systolische versus diastolische Dysfunktion. Schweiz Med Wochenschr 1994; 124: 1196-1202.
12. Nishimura R. A., Housmans P. R., Hatle L. K., Tajik A. J.: Assessment of diastolic function of the heart: background and current applications of Doppler echocardiography. Part I. Physiologic and pathophysiologic features. Mayo Clin Proc 1989; 64: 71-81.
13. Francis G. S., Benedict C., Johnstone D. E., Kirlin P. C., Nicklas J., Liang C. S., Kubo S. H., Rudin-Toretsky E., Yusuf S.: Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990; 82: 1724-1729.
14. Benedict C. R., Weiner D. H., Johnstone D. E., Bourassa M. G., Ghali J. K., Nicklas J., Kirlin P., Greenberg B., Quinones M. A., Yusuf S.: Comparative neurohormonal responses in patients with preserved and impaired left ventricular ejection fraction: results of the Studies of Left Ventricular Dysfunction (SOLVD) Registry. The SOLVD Investigators. J Am Coll Cardiol 1993; 22 (Suppl A): 146A-153A.
15. Leimbach W. N. Jr., Wallin B. G., Victor R. G., Aylward P. E., Sundlof G., Mark A. L.: Direct evidence form intraneural recordings for increased central sympathetic outflow in patients with heart failure. Circulation 1986; 73: 913-919.
16. Creager M. A., Creager S. J.: Arterial baroreflex regulation of blood pressure in patients with congestive heart failure. J Am Coll Cardiol 1994; 23: 401-405.
17. Watkins L. Jr., Burton J. A., Haber E., Cant J. R., Smith F. W., Barger A. C.: The renin-angiotensin-aldosterone system in congestive failure in conscious dogs. J Clin Invest 1976; 57: 1606-1617.
18. Dzau V. J., Colucci W. S., Hollenberg N. K., Williams G. H.: Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation 1981; 63: 645-651.
19. Pin B.: «Escape» of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. Cardiovasc Drugs Ther 1995; 9: 145-149.
20. Mizuno K., Nakamaru M., Higashimori K., Inagami T.: Local generation and release of angiotensin II in peripheral vascular tissue. Hypertension 1988; 11: 223-229.
21. Cody R. J., Haas G. J., Binkley P. F., Capers Q., Kelley R.: Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure [published erratum appears in Circulation 1993 Mar; 87(3): 1064]. Circulation 1992; 85: 504-509.
22. Drexler H., Hayoz D., Munzel T., Hornig B., Just H., Brunner H. R., Zelis R.: Endothelial function in chronic congestive heart failure. Am J Cardiol 1992; 69: 1596-1601.
23. Brandt R. R., Wright R. S., Redfield M. M., Burnett J. C. Jr.: Atrial natriuretic peptide in heart failure. J Am Coll Cardiol 1993; 22 (Suppl A): 86A-92A.
24. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685-691.
25. Packer M.: Evolution of the neurohormonal hypothesis to explain the progression of chronic heart failure. Eur Heart J 1995; 16 (Suppl F): 4-6.
26. Brilla C. G., Pick R., Tan L. B., Janicki J. S., Weber K. T.: Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 1990; 67: 1355-1364.
27. Booz G. W., Baker K. M.: Molecular signalling mechanisms controlling growth and function of cardiac fibroblasts. Cardiovasc Res 1995; 30: 537-543.
28. Lombes M., Alfaidy N., Eugene E., Lessana A., Farman N., Bonvalet J. P.: Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 1l betahydroxysteroid dehydrogenase in the human heart. Circulation 1995; 92: 175-182.
29. Brilla C. G., Maisch B., Zhou G., Weber K. T.: Hormonal regulation of cardiac fibroblast function. Eur Heart J 1995; 16 (Suppl C): 45-50.
30. Brilla C. G., Maisch B., Rupp H., Funck R., Zhou G., Weber K. T.: Pharmacological modulation of cardiac fibroblast function. Herz 1995; 20: 127-134.
31. Schunkert H., Ingelfinger J. R., Hirsch A. T., Tang S. S., Litwin S. E., Talsness C. E., Dzau V. J.: Evidence for tissue-specific activation of renal angiotensinogen mRNA expression in chronic stable experimental heart failure. J Clin Invest 1992; 90: 1523-1529.
32. Sawa H., Kawaguchi H., Mochizuki N., Endo Y., Kudo T., Tokuchi F., Fijioka Y., Nagashima K., Kitabatake A.: Distribution of angiotensinogen in diseased human hearts. Mol Cell Biochem 1994; 132: 15-23.